Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Elahere, a new antibody-drug conjugate, shrank tumors in about a third of treatment-experienced patients.
The topical cream Opzulera (ruxolitinib) can improv skin repigmentation in people with melanoma-associated vitiligo.
Pedmark (sodium thiosulfate) is the first med approved to lower risk of hearing loss in children treated with cisplatin chemotherapy.
Updated Pfizer-BioNTech and Moderna bivalent boosters contain spike proteins from the original and BA.4 and BA.5 omicron variants.
The combination of target drugs Tafinlar-Mekinist is approved for nearly any type of advanced solid tumor that has the BRAF gene mutation.
The engineered protein vaccine was highly effective in a clinical trial but faced a long delay for authorization.
This is the first investigational therapy in a Phase III trial to improve overall survival in uveal melanoma,” a cancer of the eye.
Azacitidine (Vidaza) was approved for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML).
An Army veteran, retired firefighter and farmer, Jeff Meckstroth, 65, lives in Ohio. He has Stage IV metastatic non-small-cell lung cancer.
Extra vaccine doses, monoclonal antibodies and antivirals can help prevent severe illness.
“It is a really important development for our patients."
An intravenous infusion of two immunotherapy drugs, Opdualag blocks activity of the proteins LAG-3 and PD-1.
The personalized CAR-T therapy prolonged cancer remission compared with standard therapy.
Immunocompromised people ages 12 and older are also eligible for an additional shot.
Neoadjuvant Opdivo plus chemotherapy improved outcomes for people with operable non-small-cell lung cancer.
98% of people who received the customized immunotherapy responded to the one-time treatment.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.